Bacteriophage therapy for patients with difficult to treat bacterial infections [In development]

SHTG logo

SHTG recommendation

In response to enquiries from a clinical bacteriophage specialist

What were we asked to look at

A Clinical Director for Surgery and a clinical bacteriophage specialist asked us to review the evidence for the use of bacteriophage therapy in patients with difficult to treat bacterial infections who continue to experience significant infection-related disability despite optimal management. Consultants from medical and surgical specialties across NHSScotland confirmed the relevance of this topic for the health service.

Why is this important

The incidence of antimicrobial tolerant and resistant bacterial infections is increasing worldwide, contributing to the strain on healthcare services due to longer hospital stays, rising medical costs and increased mortality.1 During 2016, it was estimated that multi-drug resistant bacterial infections alone caused 700,000 deaths globally each year; if current practices continue this figure is expected to rise to 10 million deaths by 2050.2 Bacteriophage therapy represents an option to address this problem in the near future.